nodes	percent_of_prediction	percent_of_DWPC	metapath
Dexfenfluramine—Methamphetamine—SLC6A3—Gilles de la Tourette syndrome	0.0831	1	CrCbGaD
Dexfenfluramine—HTR2B—Serotonin receptors—HTR2A—Gilles de la Tourette syndrome	0.0506	0.0552	CbGpPWpGaD
Dexfenfluramine—HTR2B—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0417	0.0455	CbGpPWpGaD
Dexfenfluramine—HTR2C—Serotonin receptors—HTR2A—Gilles de la Tourette syndrome	0.0408	0.0445	CbGpPWpGaD
Dexfenfluramine—SLC6A4—Monoamine Transport—SLC6A3—Gilles de la Tourette syndrome	0.0391	0.0426	CbGpPWpGaD
Dexfenfluramine—HTR2B—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.0356	0.0388	CbGpPWpGaD
Dexfenfluramine—HTR2B—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.0345	0.0377	CbGpPWpGaD
Dexfenfluramine—HTR2C—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0337	0.0367	CbGpPWpGaD
Dexfenfluramine—HTR2B—Serotonin Receptor 2 and ELK-SRF/GATA4 signaling—HTR2A—Gilles de la Tourette syndrome	0.0336	0.0367	CbGpPWpGaD
Dexfenfluramine—HTR2B—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.0322	0.0351	CbGpPWpGaD
Dexfenfluramine—HTR2B—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.0299	0.0326	CbGpPWpGaD
Dexfenfluramine—HTR2B—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.029	0.0317	CbGpPWpGaD
Dexfenfluramine—HTR2C—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.0287	0.0313	CbGpPWpGaD
Dexfenfluramine—HTR2C—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.0279	0.0304	CbGpPWpGaD
Dexfenfluramine—HTR2C—Serotonin Receptor 2 and ELK-SRF/GATA4 signaling—HTR2A—Gilles de la Tourette syndrome	0.0271	0.0296	CbGpPWpGaD
Dexfenfluramine—HTR2B—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.0271	0.0295	CbGpPWpGaD
Dexfenfluramine—HTR2C—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.026	0.0283	CbGpPWpGaD
Dexfenfluramine—HTR2C—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.0241	0.0263	CbGpPWpGaD
Dexfenfluramine—HTR2C—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.0234	0.0255	CbGpPWpGaD
Dexfenfluramine—HTR2B—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.0225	0.0246	CbGpPWpGaD
Dexfenfluramine—HTR2C—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.0218	0.0238	CbGpPWpGaD
Dexfenfluramine—HTR2B—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.0189	0.0207	CbGpPWpGaD
Dexfenfluramine—HTR2C—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.0182	0.0198	CbGpPWpGaD
Dexfenfluramine—HTR2C—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.0153	0.0167	CbGpPWpGaD
Dexfenfluramine—SLC6A4—NRF2 pathway—SLC6A3—Gilles de la Tourette syndrome	0.0116	0.0127	CbGpPWpGaD
Dexfenfluramine—SLC6A4—Circadian rythm related genes—DRD3—Gilles de la Tourette syndrome	0.00976	0.0106	CbGpPWpGaD
Dexfenfluramine—SLC6A4—Circadian rythm related genes—DRD4—Gilles de la Tourette syndrome	0.00947	0.0103	CbGpPWpGaD
Dexfenfluramine—SLC6A4—Circadian rythm related genes—DRD2—Gilles de la Tourette syndrome	0.00883	0.00963	CbGpPWpGaD
Dexfenfluramine—SLC6A4—SIDS Susceptibility Pathways—HTR2A—Gilles de la Tourette syndrome	0.00757	0.00826	CbGpPWpGaD
Dexfenfluramine—CYP2A6—NRF2 pathway—SLC6A3—Gilles de la Tourette syndrome	0.00738	0.00805	CbGpPWpGaD
Dexfenfluramine—HTR2B—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00687	0.00749	CbGpPWpGaD
Dexfenfluramine—HTR2B—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00667	0.00727	CbGpPWpGaD
Dexfenfluramine—HTR2B—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00621	0.00677	CbGpPWpGaD
Dexfenfluramine—HTR2B—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00588	0.00642	CbGpPWpGaD
Dexfenfluramine—HTR2B—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00571	0.00623	CbGpPWpGaD
Dexfenfluramine—HTR2B—G alpha (q) signalling events—HTR2A—Gilles de la Tourette syndrome	0.00563	0.00614	CbGpPWpGaD
Dexfenfluramine—HTR2C—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00554	0.00604	CbGpPWpGaD
Dexfenfluramine—HTR2C—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00538	0.00587	CbGpPWpGaD
Dexfenfluramine—HTR2B—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00532	0.0058	CbGpPWpGaD
Dexfenfluramine—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Gilles de la Tourette syndrome	0.00503	0.00549	CbGpPWpGaD
Dexfenfluramine—HTR2C—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00501	0.00546	CbGpPWpGaD
Dexfenfluramine—HTR2C—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00475	0.00518	CbGpPWpGaD
Dexfenfluramine—HTR2C—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00461	0.00503	CbGpPWpGaD
Dexfenfluramine—HTR2C—G alpha (q) signalling events—HTR2A—Gilles de la Tourette syndrome	0.00454	0.00495	CbGpPWpGaD
Dexfenfluramine—HTR2B—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00448	0.00489	CbGpPWpGaD
Dexfenfluramine—HTR2B—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00435	0.00474	CbGpPWpGaD
Dexfenfluramine—HTR2B—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00435	0.00474	CbGpPWpGaD
Dexfenfluramine—HTR2C—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00429	0.00468	CbGpPWpGaD
Dexfenfluramine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Gilles de la Tourette syndrome	0.00406	0.00443	CbGpPWpGaD
Dexfenfluramine—HTR2B—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00405	0.00442	CbGpPWpGaD
Dexfenfluramine—HTR2B—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00373	0.00406	CbGpPWpGaD
Dexfenfluramine—HTR2C—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00361	0.00394	CbGpPWpGaD
Dexfenfluramine—HTR2C—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00351	0.00383	CbGpPWpGaD
Dexfenfluramine—HTR2C—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00351	0.00383	CbGpPWpGaD
Dexfenfluramine—HTR2C—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00327	0.00356	CbGpPWpGaD
Dexfenfluramine—CYP2A6—Metabolism—HDC—Gilles de la Tourette syndrome	0.00318	0.00347	CbGpPWpGaD
Dexfenfluramine—HTR2C—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00301	0.00328	CbGpPWpGaD
Dexfenfluramine—HTR2B—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.00284	0.00309	CbGpPWpGaD
Dexfenfluramine—HTR2B—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.00253	0.00276	CbGpPWpGaD
Dexfenfluramine—CYP2E1—Metabolism—HDC—Gilles de la Tourette syndrome	0.00251	0.00274	CbGpPWpGaD
Dexfenfluramine—HTR2B—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.00246	0.00268	CbGpPWpGaD
Dexfenfluramine—HTR2B—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.0023	0.00251	CbGpPWpGaD
Dexfenfluramine—HTR2B—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.00229	0.0025	CbGpPWpGaD
Dexfenfluramine—HTR2C—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.00229	0.0025	CbGpPWpGaD
Dexfenfluramine—HTR2B—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.00223	0.00243	CbGpPWpGaD
Dexfenfluramine—HTR2B—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.00208	0.00227	CbGpPWpGaD
Dexfenfluramine—HTR2C—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.00204	0.00223	CbGpPWpGaD
Dexfenfluramine—HTR2C—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.00198	0.00216	CbGpPWpGaD
Dexfenfluramine—CYP2C19—Metabolism—HDC—Gilles de la Tourette syndrome	0.00194	0.00212	CbGpPWpGaD
Dexfenfluramine—HTR2C—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.00185	0.00202	CbGpPWpGaD
Dexfenfluramine—HTR2C—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.00185	0.00201	CbGpPWpGaD
Dexfenfluramine—HTR2C—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.0018	0.00196	CbGpPWpGaD
Dexfenfluramine—CYP2D6—Metabolism—HDC—Gilles de la Tourette syndrome	0.00178	0.00195	CbGpPWpGaD
Dexfenfluramine—CYP2C9—Metabolism—HDC—Gilles de la Tourette syndrome	0.00177	0.00193	CbGpPWpGaD
Dexfenfluramine—HTR2C—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.00168	0.00183	CbGpPWpGaD
Dexfenfluramine—HTR2B—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.0016	0.00175	CbGpPWpGaD
Dexfenfluramine—CYP1A2—Metabolism—HDC—Gilles de la Tourette syndrome	0.00151	0.00165	CbGpPWpGaD
Dexfenfluramine—HTR2B—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.00146	0.00159	CbGpPWpGaD
Dexfenfluramine—HTR2B—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.00136	0.00148	CbGpPWpGaD
Dexfenfluramine—HTR2B—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.00132	0.00144	CbGpPWpGaD
Dexfenfluramine—HTR2C—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.00129	0.00141	CbGpPWpGaD
Dexfenfluramine—HTR2B—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.00123	0.00134	CbGpPWpGaD
Dexfenfluramine—HTR2C—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.00117	0.00128	CbGpPWpGaD
Dexfenfluramine—HTR2C—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.0011	0.0012	CbGpPWpGaD
Dexfenfluramine—HTR2C—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.00106	0.00116	CbGpPWpGaD
Dexfenfluramine—HTR2C—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000991	0.00108	CbGpPWpGaD
Dexfenfluramine—HTR2B—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.00086	0.000938	CbGpPWpGaD
Dexfenfluramine—HTR2C—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000694	0.000757	CbGpPWpGaD
